Masaki Kato

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 39

Top Venues

Neuropsychopharmacology reports

Neuropsychiatric disease and treatment

Molecular psychiatry

Psychiatry and clinical neurosciences

Kansai Medical University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Kansai Medical University

Japan

Associate Professor :: Neuropsychiatry

Publications

Taro Kishi, Kenji Sakuma, Takeo Saito, Atsuo Nakagawa, Masaki Kato, Nakao Iwata
Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis. Neuropsychopharmacology reports (2024)
Taro Kishi, Kenji Sakuma, Takeo Saito, Atsuo Nakagawa, Masaki Kato, Nakao Iwata
Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Masaki Kato, Toshiaki Kikuchi, Koichiro Watanabe, Tomiki Sumiyoshi, Yoshiya Moriguchi, Daniel Oudin Åstrøm, Michael Cronquist Christensen
Goal Attainment Scaling for Depression: Validation of the Japanese GAS-D Tool in Patients with Major Depressive Disorder. Neuropsychiatric disease and treatment 20 (2024)
Taro Kishi, Kenji Sakuma, Takeo Saito, Atsuo Nakagawa, Masaki Kato, Nakao Iwata
Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Masaki Kato, Toshiaki Kikuchi, Koichiro Watanabe, Tomiki Sumiyoshi, Yoshiya Moriguchi, Daniel Oudin Åstrøm, Michael Cronquist Christensen
Goal Attainment Scaling for Depression: Validation of the Japanese GAS-D Tool in Patients with Major Depressive Disorder. Neuropsychiatric disease and treatment 20 (2024)
Taro Kishi, Kenji Sakuma, Takeo Saito, Atsuo Nakagawa, Masaki Kato, Nakao Iwata
Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Tadafumi Kato, Kazuyoshi Ogasawara, Keisuke Motomura, Masaki Kato, Teruaki Tanaka, Yoshikazu Takaesu, Shintaro Nio, Taro Kishi, Mirai So, Kiyotaka Nemoto, Eiji Suzuki, Koichiro Watanabe, Koji Matsuo, null null, null null, null null
Practice Guidelines for Bipolar Disorder by the JSMD (Japanese Society of Mood Disorders). Psychiatry and clinical neurosciences (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports (2024)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports 44 (1) (2024)
Masaki Kato, Hiroshi Tsuda, Yirong Chen, Toshinaga Tsuji, Nobuhiro Nishigaki
The Burden of Attention-Deficit/Hyperactivity Disorder Traits in Adult Patients with Major Depressive Disorder in Japan. Neuropsychiatric disease and treatment 19 (2023)
Masaki Kato, Toshiaki Kikuchi, Koichiro Watanabe, Tomiki Sumiyoshi, Yoshiya Moriguchi, Daniel Oudin Åstrøm, Michael Cronquist Christensen
Assessing Reliability and Validity of the Oxford Depression Questionnaire (ODQ) in a Japanese Clinical Population. Neuropsychiatric disease and treatment 19 (2023)
Yoshiteru Takekita, Shuichi Hiraoka, Yasuhiro Iwama, Daisuke Matsui, Nobuatsu Aoki, Haruhiko Ogata, Toshiya Funatsuki, Toshiyuki Shimizu, Yuji Murase, Yosuke Koshikawa, Masaki Kato, Toshihiko Kinoshita
Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real-world data. Neuropsychopharmacology reports (2023)
Masaki Kato, Hiroshi Tsuda, Yirong Chen, Toshinaga Tsuji, Nobuhiro Nishigaki
The Burden of Attention-Deficit/Hyperactivity Disorder Traits in Adult Patients with Major Depressive Disorder in Japan. Neuropsychiatric disease and treatment 19 (2023)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, Satoru Esumi, Nobumi Miyake, Itaru Miura, Hikaru Hori, Masaki Kato, Nakao Iwata
Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacology reports (2023)
Masaki Kato, Masako Shiosakai, Kazuo Kuwahara, Katsuhiro Iba, Yuki Shimada, Mizuki Saito, Yuki Isogai, Daisuke Sekine, Kazuo Aoki, Nobuyuki Koga, Teruhiko Higuchi
Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study. Psychiatry and clinical neurosciences (2023)
Masaki Kato, Kazuyuki Nakagome, Takamichi Baba, Takuhiro Sonoyama, Daiki Okutsu, Hideki Yamanaka, Ryosuke Shimizu, Tomoko Motomiya, Takeshi Inoue
Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial. Psychiatry and clinical neurosciences (2023)
Naoto Adachi, Yukihisa Kubota, Eiichiro Goto, Koichiro Watanabe, Reiji Yoshimura, Takashi Tsuboi, Yasui-Furukori Norio, Masaki Kato, Seiji Hongo, Takaharu Azekawa, Eiichi Katsumoto, Koji Edagawa, Atsuo Nakagawa, Toshiaki Kikuchi, Hitoshi Ueda, Kazuhira Miki
Costs of psychotropics for outpatients with bipolar disorder in Japan; the MUSUBI 2016 survey. Annals of medicine 55 (1) (2023)
Toshiya Funatsuki, Haruhiko Ogata, Hidetoshi Tahara, Akira Shimamoto, Yoshiteru Takekita, Yosuke Koshikawa, Shinpei Nonen, Koichiro Higasa, Toshihiko Kinoshita, Masaki Kato
Changes in Multiple microRNA Levels with Antidepressant Treatment Are Associated with Remission and Interact with Key Pathways: A Comprehensive microRNA Analysis. International journal of molecular sciences 24 (15) (2023)
Masaki Kato, Hikaru Hori, Aran Tajika
Appropriate duration of antidepressant medications for prevention of depressive relapse and the impact of life stage. Molecular psychiatry (2023)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Makoto Okuya, Yuki Matsuda, Masaki Kato, Masashi Ikeda
Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. Molecular psychiatry 28 (3) (2022)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Makoto Okuya, Yuki Matsuda, Masaki Kato, Masashi Ikeda
Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. Molecular psychiatry 28 (3) (2022)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Makoto Okuya, Yuki Matsuda, Masaki Kato, Masashi Ikeda
Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. Molecular psychiatry 28 (3) (2022)
Yumi Aoki, Yoshikazu Takaesu, Hajime Baba, Jun-Ichi Iga, Hikaru Hori, Takeshi Inoue, Kazuo Mishima, Aran Tajika, Masaki Kato
Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission. Neuropsychopharmacology reports 42 (3) (2022)
Aran Tajika, Hikaru Hori, Jun-Ichi Iga, Yosuke Koshikawa, Haruhiko Ogata, Yusuke Ogawa, Koichiro Watanabe, Tadafumi Kato, Koji Matsuo, Masaki Kato
Mood Stabilizers and Antipsychotics for Acute Mania: Systematic Review and Meta-Analysis of Augmentation Therapy vs Monotherapy From the Perspective of Time to the Onset of Treatment Effects. The international journal of neuropsychopharmacology 25 (10) (2022)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Makoto Okuya, Yuki Matsuda, Masaki Kato, Masashi Ikeda
Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. Molecular psychiatry (2022)
Masaki Kato, Haruhiko Ogata, Hidetoshi Tahara, Akira Shimamoto, Yoshiteru Takekita, Yosuke Koshikawa, Keiichiro Nishida, Shinpei Nonen, Koichiro Higasa, Toshihiko Kinoshita
Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways. International journal of molecular sciences 23 (7) (2022)
Kiyokazu Atake, Hikaru Hori, Yuki Kageyama, Yosuke Koshikawa, Ryohei Igata, Hirotaka Tominaga, Asuka Katsuki, Hiroki Bando, Shiho Sakai, Keiichiro Nishida, Yoshiteru Takekita, Tadafumi Kato, Toshihiko Kinoshita, Masaki Kato
Pre-treatment plasma cytokine levels as potential predictors of short-term remission of depression. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (2022)
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Makoto Okuya, Yuki Matsuda, Masaki Kato, Masashi Ikeda
Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. Molecular psychiatry 28 (3) (2022)
Yusuke Konno, Yoshihisa Fujino, Atsuko Ikenouchi, Naoto Adachi, Yukihisa Kubota, Takaharu Azekawa, Hitoshi Ueda, Koji Edagawa, Eiichi Katsumoto, Eiichiro Goto, Seiji Hongo, Masaki Kato, Takashi Tsuboi, Yasui-Furukori Norio, Atsuo Nakagawa, Toshiaki Kikuchi, Koichiro Watanabe, Reiji Yoshimura
Relationship Between Mood Episode and Employment Status of Outpatients with Bipolar Disorder: Retrospective Cohort Study from the Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Clinics (MUSUBI) Project. Neuropsychiatric disease and treatment 17 (2021)
Keita Tokumitsu, Yasui-Furukori Norio, Naoto Adachi, Yukihisa Kubota, Yoichiro Watanabe, Kazuhira Miki, Takaharu Azekawa, Koji Edagawa, Eiichi Katsumoto, Seiji Hongo, Eiichiro Goto, Hitoshi Ueda, Masaki Kato, Atsuo Nakagawa, Toshiaki Kikuchi, Takashi Tsuboi, Koichiro Watanabe, Kazutaka Shimoda, Reiji Yoshimura
Real-world clinical predictors of manic/hypomanic episodes among outpatients with bipolar disorder. PloS one 16 (12) (2021)
Takashi Tsuboi, Takefumi Suzuki, Takaharu Azekawa, Naoto Adachi, Hitoshi Ueda, Kouji Edagawa, Eiichi Katsumoto, Yukihisa Kubota, Eiichiro Goto, Seiji Hongo, Yoichiro Watanabe, Masaki Kato, Norio Yasui-Furukori, Reiji Yoshimura, Atsuo Nakagawa, Toshiaki Kikuchi, Koichiro Watanabe
Factors Associated with Non-Remission in Bipolar Disorder: The Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI). Neuropsychiatric disease and treatment 16 (2020)
Masaki Kato, Hikaru Hori, Takeshi Inoue, Jun-Ichi Iga, Masaaki Iwata, Takahiko Inagaki, Kiyomi Shinohara, Hissei Imai, Atsunobu Murata, Kazuo Mishima, Aran Tajika
Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Molecular psychiatry 26 (1) (2020)
Hitoshi Sakurai, Masaki Kato, Norio Yasui-Furukori, Takefumi Suzuki, Hajime Baba, Koichiro Watanabe, Ken Inada, Ikuko Kishida, Yuka Sugawara Kikuchi, Toshiaki Kikuchi, Asuka Katsuki, Hiroyuki Uchida, null null
Pharmacological management of bipolar disorder: Japanese expert consensus. Bipolar disorders 22 (8) (2020)

Masaki Kato.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Masaki Kato